|
May 25, 2012
|
| 11:09 EDT |  | TEVA |
|
| 08:17 EDT | | TEVA |
|
| 07:10 EDT | | TEVA |
| theflyonthewall.com: | Teva price target lowered to $52 from $60 at UBS | | UBS lowered Teva's price target following the company's lowered guidance. The firm continues to rate shares a Buy and sees value at current prices. :theflyonthewall.com |
|
| 06:07 EDT |  | HSP |
| theflyonthewall.com: | Theravance to transfer certain technology related to VIBATIV to Hospira | | On May 22, Theravance (THRX) signed a Technology Transfer and Supply Agreement with Hospira Worldwide (HSP). The Agreement provides for the Company to transfer certain manufacturing technology to Hospira related to its VIBATIV drug product, and make technology transfer payments to Hospira as Hospira undertakes and completes technology transfer and validation activities. Once regulatory approval for Hospira to manufacture VIBATIV has been obtained, Hospira will manufacture and sell VIBATIV to the Company pursuant to the Agreement. The Agreement has a five-year term, subject to earlier termination following bankruptcy, uncured breaches or inability to perform. Theravance has agreed, subject to certain conditions and exceptions, to purchase from Hospira more than a majority of its VIBATIV 750 mg dosage form requirements during the term. :theflyonthewall.com |
|
|
May 24, 2012
|
| 14:26 EDT | | TEVA |
|
| 09:45 EDT |  | TEVA |
|
| 09:41 EDT |  | TEVA |
|
| 08:38 EDT | | TEVA |
| theflyonthewall.com: | Teva volatility elevated into 2012 sales guidance of $20B-$21B | | Teva May overall option implied volatility of 30 is above its 26-week average of 27 according to Track Data, suggesting larger price movement into the company seeing 2012 sales $20B-$21B. :theflyonthewall.com |
|
| 08:29 EDT | | TEVA |
|
| 08:27 EDT |  | TEVA |
| theflyonthewall.com: | Teva sees FY generic product net sales approximately $10.7B | | Consists of U.S. generic sales of $4.6B, European generic sales of $3.4B, and ROW generic sales of $2.7B. Sees brand product net sales of approximately $8B. Sees FY TREANDA sales $580M, PROVIGIL sales $420M, AZILECT sales $340M. :theflyonthewall.com |
|
| 08:24 EDT | | TEVA |
| theflyonthewall.com: | Teva says committed to transparency | | Says not giving guidance for 2013 at this stage. :theflyonthewall.com |
|
| 08:21 EDT | | TEVA |
|
| 08:19 EDT | | TEVA |
|
| 08:19 EDT | | TEVA |
| theflyonthewall.com: | Teva sees Copaxone sales of $3.8B this year | | Says continuing to expect and model Copaxone sales to pick this year and then to start a steady decline to 2015. :theflyonthewall.com |
|
| 08:18 EDT | | TEVA |
|
| 08:17 EDT | | TEVA |
|
| 08:16 EDT | | TEVA |
| theflyonthewall.com: | Teva says sees FY12 EPS $5.30-$5.40, consensus $5.59 | | Says expects total net sales of approximately $20B-$21B, consisting of total U.S. net sales $10.5B, total European net sales $5.8B, total rest of world sales of $4.2B. Revenue consensus is $21.27B. Comments made on Teva's 2012 Business Outlook Update Conference Call. :theflyonthewall.com |
|
| 05:50 EDT | | TEVA |
|
| 05:42 EDT |  | TEVA |
| theflyonthewall.com: | Teva to host business news update conference call | | Conference call to be held on May 24 at 8 am. Webcast Link :theflyonthewall.com |
|
|
May 23, 2012
|
| 11:46 EDT |  | TEVA |
| theflyonthewall.com: | BioLineRx CFO says approached about schizophrenia pill, Bloomberg reports | | The CFO of BioLineRx (BLRX), which is partly held by Teva Pharmaceutical (TEVA), said it’s been approached by larger drugmakers interested in developing its experimental schizophrenia pill and sees partnership talks to likely “heat up” when the company gets results expected next year from a more advanced study of its BL-1020 experimental drug, reported Bloomberg, citing Serlin's comments yesterday in an interview at the ILSI-Biomed Conference in Tel Aviv. Reference Link :theflyonthewall.com |
|
| 08:14 EDT |  | TEVA |
|
| 07:10 EDT | | TEVA |
| theflyonthewall.com: | FTC, Senate probing blocking of generic drug companies, Washington Post says | | The Federal Trade Commission and the U.S. Senate are investigating whether pharmaceutical companies are using a loophole to prevent generic drug makers from obtaining samples of brand name drugs, according to The Washington Post. The FDA requires generic drug makers to test a sample of brand name versions in order to get a generic drug approved, the newspaper notes. Reference Link :theflyonthewall.com |
|
|
May 17, 2012
|
| 15:47 EDT | | TEVA |
|
| 08:02 EDT | | TEVA |
| theflyonthewall.com: | Teva, Ambit Biosciences announce clearance of IND app for CEP-32496 | | Ambit Biosciences and Teva Pharmaceutical Industries announced the clearance of an Investigational New Drug application, or IND, with the U.S. Food and Drug Administration for CEP-32496, a novel BRAF kinase inhibitor. :theflyonthewall.com |
|
|
May 14, 2012
|
| 06:22 EDT | | HSP |
|
| 06:20 EDT | | HSP |
| theflyonthewall.com: | Hospira initiating recall of Hydrochloride Injection lot, FDA says | | The FDA announced on Saturday that Hospira is initiating a voluntary user level recall of one lot of Hydromorphone Injection due to two reported complaints of a single Carpuject containing more than the 1 mL labeled fill volume. Opioid pain medications such as Hydromorphone have life-threatening consequences if overdosed, the FDA warned. Reference Link :theflyonthewall.com |
|
Subscribe for More Information